Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin vs Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
NCT02249702Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Apr 2010
- Primary completion
- Apr 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin in uterine leiomyosarcoma (uLMS), sponsored by Mario Negri Institute for Pharmacological Research. Started Apr 2010; status: completed.
02
Drugs
trabectedin
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT02249702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249702.